Akeso (HKG:9926) said China's National Medical Products Administration approved the new drug application for its cholesterol drug PCSK9, according to a Monday filing with the Hong Kong bourse.
Ebronucimab is intended to lower fasting serum low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), non-high-density lipoprotein cholesterol (Non-HDL-C), and apolipoprotein B (ApoB) while increasing high-density lipoprotein cholesterol (HDL-C), and it also helps lower the risk of cardiac events, the filing said.
Price (HKD): $68.60, Change: $+1.2, Percent Change: +1.78%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments